Story
Oncology Drug Developer Genhouse Bio Refiles for Hong Kong IPO

Chinese biopharmaceutical company Genhouse Bio has officially refiled for an initial public offering on the main board of the Hong Kong Stock Exchange (HKEX), marking its second attempt to go public this year. According to an exchange disclosure on August 7, Huatai International is acting as the sole sponsor for the proposed listing.
Second Listing Attempt
This latest application follows the lapse of Genhouse Bio's previous submission. The company first filed for a Hong Kong IPO in January, but that application expired in July after the standard six-month review period without a hearing.
The renewed filing restarts the listing process, signaling the company's continued commitment to accessing public capital markets to fund its research and development activities.
Oncology-Focused Pipeline
AdFounded in 2014, Genhouse Bio focuses on developing innovative targeted therapies for cancer. The company's pipeline is centered around the RAS signaling pathway and synthetic lethality mechanisms, two key areas in modern oncology research.
According to its prospectus, the company has eight drug candidates in development. Key details include:
- Core Product: The lead asset is GH21, an allosteric SHP2 inhibitor.
- Clinical Stage: GH21 is currently in Phase 2 clinical trials.
- Positioning: The company describes GH21 as a potential best-in-class therapy in its category.
A successful IPO would provide significant capital for Genhouse Bio to advance GH21 through later-stage clinical trials and further develop its broader pipeline of cancer treatments.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.